Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present). (2nd September 2021)

• Record Type: Journal Article
• Authors: Adekiya, Tayo A.; Kumar, Pradeep; Kondiah, Pierre P.D.; Pillay, Viness; Choonara, Yahya E.
• Is Part Of: Expert opinion on therapeutic patents. Volume 31:Number 9(2021)
• Page Start: 851
• Page End: 865
• Publication Date: 2021-09-02
• Subjects: Praziquantel -- schistosomiasis -- drug delivery -- lipid-based nanosystems -- patent -- synthesis; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2021.1915292
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction: : Among all the anti-schistosomal drugs, praziquantel has been the most widely used. However, some major challenges have been faced using the drug in the treatment of schistosome infections. Areas covered: : Several approaches used in the synthesis of praziquantel aimed at reducing the time and cost of production, the toxicity and experimental harsh conditions are discussed. Also, patented methods involved in the pharmaceutical reformulation of praziquantel in the treatment of diverse endoparasitic infestations are reported. Additionally, future perspectives in terms of nanomedicine approach in the formulation of praziquantel are highlighted. Expert Opinion: : Lipid-based nanosystems (LBNSs) formulations can be used to overcome the shortcomings associated with the use of praziquantel in the schistosomiasis treatment due to their amphipathic nature. This could be a promising vehicle for the delivery of praziquantel, which could in turn improve the bioavailability, as well as reduce the frequent dose of the drug and improve patient compliance. This may sustain the release of the drug and improve the rapid conversion of the drug into inactive metabolite due to rapid metabolism. Additionally, LBNSs approach could increase and improve the lipophilicity of the drug, which could make it easier to interact with the hydrophobic cores of the worm tegument.